- Trials with a EudraCT protocol (869)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
869 result(s) found for: Adult day care.
Displaying page 1 of 44.
EudraCT Number: 2020-002913-16 | Sponsor Protocol Number: 0135-0347 | Start Date*: 2020-11-26 | |||||||||||
Sponsor Name:SCS Boehringer Ingelheim Comm. V | |||||||||||||
Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome caused by Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006644-27 | Sponsor Protocol Number: CARR-ARDS-2021 | Start Date*: 2023-02-28 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA UDINE | |||||||||||||
Full Title: Efficacy and safety of anakinra in non-COVID-19 related ARDS. ESKA study. | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001078-27 | Sponsor Protocol Number: 19999 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Safety and efficacy of inhaled pegylated adrenomedullin (PEG-ADM) in patients suffering from Acute Respiratory Distress Syndrome (ARDS): a double-blind, randomized, placebo-controlled, multicenter ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) CZ (Completed) AT (Prematurely Ended) IT (Prematurely Ended) GR (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DK (Prematurely Ended) IE (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001612-25 | Sponsor Protocol Number: REP0122 | Start Date*: 2022-10-12 | |||||||||||
Sponsor Name:DOMPé FARMACEUTICI S.P.A. | |||||||||||||
Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ... | |||||||||||||
Medical condition: Acute Respiratory Distress Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-020403-75 | Sponsor Protocol Number: ACEmeVent-Pilot | Start Date*: 2011-10-24 | ||||||||||||||||
Sponsor Name:Universität Leipzig | ||||||||||||||||||
Full Title: ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial | ||||||||||||||||||
Medical condition: acute lung injury, ALI/ARDS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005306-25 | Sponsor Protocol Number: Pioneer | Start Date*: 2021-09-15 | |||||||||||
Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||
Full Title: PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial (PIONEER) GR-2019-12371063 | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000598-95 | Sponsor Protocol Number: HS-20-674 | Start Date*: 2021-07-30 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 2, randomized, double-blind, placebo-controlled, multi-center trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) in patients with acute respiratory distress ... | |||||||||||||
Medical condition: Acute respiratory distress syndrome (ARDS) caused by COVID-19 or other disorders | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005883-78 | Sponsor Protocol Number: CHRD1520 | Start Date*: 2021-02-05 | |||||||||||||||||||||||||||||||
Sponsor Name:Hospital Center rené Dubos | |||||||||||||||||||||||||||||||||
Full Title: Comparison of Prednisolone and Dexamethasone on D28 mortality in patients on oxygen therapy with CoViD-19 | |||||||||||||||||||||||||||||||||
Medical condition: Care of severe forms of CoViD-19 from the transitional phase and the onset of the inflammatory phase with corticosteroids | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001270-29 | Sponsor Protocol Number: EFC16858 | Start Date*: 2020-04-08 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: An adaptive Phase 2/3, randomized, open-label study assessing efficacy and safety of hydroxychloroquine for hospitalized patients with moderate to severe COVID-19 | |||||||||||||
Medical condition: Coronavirus infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003486-19 | Sponsor Protocol Number: 1.002.20 | Start Date*: 2020-10-08 | ||||||||||||||||||||||||||
Sponsor Name:University of Dundee | ||||||||||||||||||||||||||||
Full Title: A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con... | ||||||||||||||||||||||||||||
Medical condition: Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001618-39 | Sponsor Protocol Number: CL08-ORY-2001_COVID-19 | Start Date*: 2020-04-24 | |||||||||||
Sponsor Name:Oryzon Genomics S. A. | |||||||||||||
Full Title: A Phase II, randomized, open–label study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress... | |||||||||||||
Medical condition: Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001244-26 | Sponsor Protocol Number: COV-2-SOLNATIDE-20 | Start Date*: 2020-04-11 | ||||||||||||||||
Sponsor Name:Department of Clinical Pharmacology, Medical University of Vienna, Vienna Austria | ||||||||||||||||||
Full Title: COVID-19: Efficacy of solnatide to treat pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS - a pilot-trial. | ||||||||||||||||||
Medical condition: Pulmonary permeability oedema in SARS-Cov-2 positive patients with moderate-to-severe ARDS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-005260-15 | Sponsor Protocol Number: FPCLI002 | Start Date*: 2016-02-10 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase III Double-blind, Randomised, Parallel Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Treatment of Patients with Modera... | |||||||||||||
Medical condition: Adult patients diagnosed with moderate or severe Acute Respiratory Distress Syndrome (ARDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FI (Prematurely Ended) BE (Completed) ES (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003855-47 | Sponsor Protocol Number: AP301-II-002 | Start Date*: 2018-02-27 | ||||||||||||||||
Sponsor Name:Apeptico Forschung und Entwicklung GmbH | ||||||||||||||||||
Full Title: Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability oedema in patients with moderate-to-severe ARDS - a randomised, placebo-controlle... | ||||||||||||||||||
Medical condition: pulmonary permeability oedema in patients with moderate-to-severe ARDS | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) DE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002345-42 | Sponsor Protocol Number: 998 | Start Date*: 2020-08-26 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: A randomized, placebo controlled, double-blind, multi-center, phase II trial investigating the efficacy and safety of trimodulin (BT588) as add-on therapy to standard of care in adult subjects with... | |||||||||||||
Medical condition: Severe Corona Virus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004146-18 | Sponsor Protocol Number: CCR3549 | Start Date*: 2011-11-09 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust | |||||||||||||
Full Title: Cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) versus gemcitabine, cisplatin and methyl prednisolone (GEM-P) in the first line treatment Of T-cell Lymphoma, a multicentre rando... | |||||||||||||
Medical condition: T-cell Lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002500-24 | Sponsor Protocol Number: AOSD.2014.001 | Start Date*: 2015-02-19 | |||||||||||
Sponsor Name:AB2 Bio Ltd. | |||||||||||||
Full Title: Open-label, multicenter, dose-escalating phase II study to investigate the safety, tolerability, and early signs of efficacy of subcutaneous administrations of Tadekinig alfa (IL-18BP) in patients ... | |||||||||||||
Medical condition: Adult -onset Still’s Disease (AoSD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000863-98 | Sponsor Protocol Number: GlucoTab@MobileCare | Start Date*: 2018-06-25 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A single-centre, open-label, non-controlled trial of acceptance, usability, safety and efficacy of a tablet based workflow and decision support system with incorporated basal-insulin algorithm for ... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002219-25 | Sponsor Protocol Number: ITCA650-CLP-107 | Start Date*: 2014-09-16 | |||||||||||
Sponsor Name:Intarcia Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes | |||||||||||||
Medical condition: Type 2 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) EE (Completed) FI (Completed) DE (Completed) DK (Completed) ES (Completed) PL (Completed) BG (Completed) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000955-25 | Sponsor Protocol Number: ClinDiab-08 | Start Date*: 2017-05-12 | |||||||||||
Sponsor Name:Medical University of Graz | |||||||||||||
Full Title: A single-centre, open-label, randomized controlled trial of efficacy, safety and usability of a basal insulin algorithm incorporated in the GlucoTab system compared to standard care for glycaemic m... | |||||||||||||
Medical condition: Diabetes mellitus type 2 | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
